Liu Y, Mack J, Shojaee M, Shaver A, George A, Clarke W
ACS Sens. 2023; 9(1):228-235.
PMID: 38110361
PMC: 10826698.
DOI: 10.1021/acssensors.3c01868.
Al Jalali V, Bauer M, Wolfl-Duchek M, Sarhan M, Wicha S, Poschner S
Clin Pharmacokinet. 2022; 62(1):77-87.
PMID: 36471223
PMC: 9898326.
DOI: 10.1007/s40262-022-01190-7.
van Groesen E, Innocenti P, Martin N
ACS Infect Dis. 2022; 8(8):1381-1407.
PMID: 35895325
PMC: 9379927.
DOI: 10.1021/acsinfecdis.2c00253.
Coraca-Huber D, Steixner S, Najman S, Stojanovic S, Finze R, Rimashevskiy D
Antibiotics (Basel). 2022; 11(7).
PMID: 35884224
PMC: 9312243.
DOI: 10.3390/antibiotics11070969.
Bian X, Qu X, Zhang J, Nang S, Bergen P, Zhou Q
Adv Drug Deliv Rev. 2022; 183:114171.
PMID: 35189264
PMC: 10019944.
DOI: 10.1016/j.addr.2022.114171.
Prediction of Unbound Vancomycin Levels in Intensive Care Unit and Nonintensive Care Unit Patients: Total Bilirubin May Play an Important Role.
Li X, Xu W, Li R, Guo Q, Li X, Sun J
Infect Drug Resist. 2021; 14:2543-2554.
PMID: 34239310
PMC: 8259942.
DOI: 10.2147/IDR.S311231.
Clinical Pharmacokinetics of Vancomycin in Critically Ill Children.
Sridharan K, Al Daylami A, Ajjawi R, Al-Ajooz H, Veeramuthu S
Eur J Drug Metab Pharmacokinet. 2019; 44(6):807-816.
PMID: 31301023
DOI: 10.1007/s13318-019-00568-6.
In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.
Thabit A, Nicolau D, Kuti J
Antimicrob Agents Chemother. 2015; 60(1):222-8.
PMID: 26482306
PMC: 4704209.
DOI: 10.1128/AAC.02033-15.
A novel murine model of established Staphylococcal bone infection in the presence of a fracture fixation plate to study therapies utilizing antibiotic-laden spacers after revision surgery.
Inzana J, Schwarz E, Kates S, Awad H
Bone. 2014; 72:128-36.
PMID: 25459073
PMC: 4282971.
DOI: 10.1016/j.bone.2014.11.019.
A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?.
Baietto L, Corcione S, Pacini G, Di Perri G, DAvolio A, De Rosa F
Curr Drug Metab. 2014; 15(6):581-98.
PMID: 24909419
PMC: 4435065.
DOI: 10.2174/1389200215666140605130935.
Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.
Lemaire S, Mingeot-Leclercq M, Tulkens P, Van Bambeke F
Antimicrob Agents Chemother. 2014; 58(4):2059-66.
PMID: 24449768
PMC: 4023769.
DOI: 10.1128/AAC.02475-13.
In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
Bhalodi A, Hagihara M, Nicolau D, Kuti J
Antimicrob Agents Chemother. 2013; 58(2):672-7.
PMID: 24217694
PMC: 3910832.
DOI: 10.1128/AAC.01516-13.
In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.
Hagihara M, Wiskirchen D, Kuti J, Nicolau D
Antimicrob Agents Chemother. 2011; 56(1):202-7.
PMID: 22006007
PMC: 3256059.
DOI: 10.1128/AAC.05473-11.
Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration.
Yamamoto T, Yasuno N, Katada S, Hisaka A, Hanafusa N, Noiri E
Antimicrob Agents Chemother. 2011; 55(12):5804-12.
PMID: 21911561
PMC: 3232773.
DOI: 10.1128/AAC.01758-10.
Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.
Butterfield J, Patel N, Pai M, Rosano T, Drusano G, Lodise T
Antimicrob Agents Chemother. 2011; 55(9):4277-82.
PMID: 21670191
PMC: 3165330.
DOI: 10.1128/AAC.01674-10.
Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
Crandon J, Kuti J, Nicolau D
Antimicrob Agents Chemother. 2010; 54(12):5115-9.
PMID: 20837760
PMC: 2981287.
DOI: 10.1128/AAC.00062-10.
Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.
Lo Y, van Hasselt J, Heng S, Lim C, Lee T, Charles B
Antimicrob Agents Chemother. 2010; 54(6):2626-32.
PMID: 20385872
PMC: 2876370.
DOI: 10.1128/AAC.01370-09.
Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.
Blanchet B, Jullien V, Vinsonneau C, Tod M
Clin Pharmacokinet. 2008; 47(10):635-54.
PMID: 18783295
DOI: 10.2165/00003088-200847100-00002.
Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.
Kollef M
Eur J Clin Microbiol Infect Dis. 2005; 24(12):794-803.
PMID: 16341681
DOI: 10.1007/s10096-005-0053-3.
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.
Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K
Antimicrob Agents Chemother. 2004; 48(4):1159-67.
PMID: 15047516
PMC: 375245.
DOI: 10.1128/AAC.48.4.1159-1167.2004.